Trial Profile
A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Metenkefalin/tridecactide (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Bosnalijek
- 07 Feb 2023 Planned End Date changed from 31 Mar 2023 to 1 Jul 2024.
- 07 Feb 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2023.
- 03 Apr 2020 Planned End Date changed from 4 Sep 2022 to 31 Mar 2023.